531 Views

Instructional Course

Instructional Course - Available with the Platinum and Silver packages or Individual Course Ticket

079IC - Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider

Monday, May 16, 2022

10:00 AM – 12:00 PM

Location: Room 208

Instructional Course Director(s)

Costas D. Lallas, MD, FACS

Professor and Vice Chair
Thomas Jefferson University Hospital

Instructional Course Faculty(s)

Edouard J. Trabulsi, MD, MBA (he/him/his)

Professor and Chair
Albert Einstein Medical Center
Anne E. Lizardi-Calvaresi, DNP (she/her/hers)

Director of Clinical Operations
Thomas Jefferson University

Learning Objectives:

Describe the standard of care chemotherapy regimens for genitourinary malignancies.
Recall both historical and newer immunotherapy options in the treatment of genitourinary malignancies (prostate, bladder, kidney), including recently approved checkpoint inhibitors and antibody-drug conjugates.
Recognize and manage the adverse events related to these agents and the survivorship issues surrounding patients on systemic treatments for genitourinary malignancies.
List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies.

We will review updated National Comprehensive Cancer Network® (NCCN®) guidelines for advanced prostate, bladder and kidney cancers, and the trials that helped to structure the guidelines. This will be the sixth year of the course given at the AUA annual meeting.